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Identity 
Other names: Biliary tract carcinoma, 
cholangiocarcinoma 
Note: Defined as a malignant epithelial tumor arising 
in the gall bladder and extrahepatic bile ducts including 
ampulla of Vater. 
Classification 
Note: Tumor staging is separated by TNM 
classification (International Classification of Diseases, 
ICD). 
TNM classifications for carcinomas of the gallbladder, 
extrahepatic bile ducts and the ampulla of Vater. 
The histopathological classification of biliary tract 
carcinoma follows WHO classification:  
- adenocarcinoma, 
- adenosquamous carcinoma, 
- squamous cell carcinoma, 
- small cell carcinoma, 
- adenoendocrine cell carcinoma, 
- undifferentiated carcinoma, and 
- carcinosarcoma. 
Clinics and pathology 
Disease  
Carcinoma of the gallbladder and extrahepatic bile 
ducts is an aggressive malignancy with a poor 
prognosis. 
Etiology 
Carcinoma of the gallbladder and extrahepatic bile 
ducts is more common in Eastern Europe and Latin 
American countries, and in the yellow races. It occurs 
frequently in older age groups (6th to 7th decades of 
life). Statistical data in Japan and USA indicate that 
gallbladder carcinomas occur predominantly in female, 
whereas carcinoma of the extrahepatic bile duct occurs 
more frequently in males. Carcinoma of the 
extrahepatic bile duct is associated with primary 
sclerosing cholangitis, ulcerative colitis, abnormal 
choledochopancreatic junction, and parasitic infection 
(trematode). In gallbladder carcinomas, gallstones and
abnormal choledochopancreatic junction are considered 
risk factors. Association with smoking and drinking is 
not established. 
Epidemiology 
One of the common carcinomas worldwide. 
Clinics 
The clinical symptoms are affected by the 
complications such as gallstones and cholangitis. The
most frequent symptom is right upper quadrant pain in 
gallbladder carcinomas and obstructive jaundice in 
extrahepatic bile duct carcinomas. Chills and fever 
appear when cholangitis develops. For early diagnosis, 
ultrasonography is useful; detection of biliary dilatation 
and tumor masses. For staging, computed tomography, 
magnetic resonance imaging, and endoscopic 
ultrasonography are effective. Percutaneous 
transhepatic cholangiography and endoscopic 
retrograde cholangiography are poorly available for 
qualitative diagnosis but performed in case of biliary 
drainage. 
Cytology 
Cytology of bile duct brushings is an important 
diagnostic tool for tumors of biliary ductal system 
presenting as duct strictures from which it can be 
difficult to obtain a histology biopsy. Bile duct 
brushings have been recognized as a technique
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Extrahepatic bile duct carcinoma from the middle portion (percutaneous transhepatic cholangiography). 
of moderate sensitivity and high specificity in 
identifying carcinoma. Reported diagnostic sensitivities 
for malignancy have ranged from 20 to 70% and 
specificity is almost 100%. Therefore, positive 
diagnoses of malignancy are of great clinical value b t 
a negative result is relatively little clinical aid. 
Treatment 
Surgical resection, chemotherapy, radiotherapy, 
immunotherapy. 
Evolution 
Recurrence should be given care to. 
Prognosis 
The prognosis of biliary carcinomas depends primarily 
on the extent of disease. In inoperable cases, one-year 
survival rates in gallbladder carcinomas and 
extrahepatic bile duct carcinomas are 10% or less and 
20% or less, respectively. 
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Positive bile cytology specimen (Papanicolau stain). Isolated cells with increased nucleocytoplasmic ratio, marked anisocaryosis, loss of 
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Cytogenetics 
Note: Loss of heterozygosity at chromosomal loci 8p, 
9p, and 18q are frequently detected. 






Proto-oncogene. GTP-GDP binding protein with 
GTPase activity. The K-ras proto-oncogene is thought 
to exert control over some of the mechanisms of cell 
growth and differentiation. This gene is converted to an 
active oncogene by point mutations significantly 
concentrated in codons 12, 13, or 61. The incidence of 
the mutations has variously been reported to be 17-59% 
of gallbladder carcinomas and 23-100% of bile duct 
carcinomas. K-ras mutations in biliary tract carcinomas 
with a background of pancreaticobiliary maljunction is 
significantly higher than in those without it, namely, 
50-100% and 6-36%, respectively. Alteration of the K-
ras oncogene may be very important in the early stage  
of carcinogenesis of biliary mucosa, especially in 
association with anomalous connections of the 
pancreatobiliary ducts. K-ras mutation is more 
frequently detected in carcinomatous and dysplastic 
lesions in gallbladder carcinoma cases with gall stones 
than in those without stones. There was a large 
difference in the incidence of K-ras mutations between 
distal (47-75%) and middle or proximal (0-8%) bile 
duct carcinoma. The distal portion may be to some 
extent influenced by pancreatic juice because of its 
anatomical location. K-ras mutations in biliary tract 
carcinomas are not statistically significantly correlated 
with tumor staging, histological type and age, sex, or 






Tumor suppressor. Wild-type p53 plays an important 
role in the regulation of the cell cycle process, cell 
growth, and apoptosis in the event of DNA damage. 
The mutant proteins from the mutated genes disrupt 
critical growth-regulating mechanisms and may play a 
crucial role in the carcinogenesis. The reported 
incidence of p53 mutation is 31-92% in gallbladder 
carcinoma and 33-73% in bile duct carcinoma. In 
general, there is a tendency for higher grade 
carcinomas to express more p53 protein. p53  
abnormalities may appear early during the transition 
from low-grade to higher-grade tumors and may play a 
role in the development of more malignant tumor 
phenotypes. A statistically significant difference is 
found for the incidence of p53 protein expression 
between extrahepatic bile duct carcinomas from the 
distal portion and those from the lower mid-region. 
This tendency is the same as that for K-ras mutations 
and the pancreaticobiliary maljunction may override 






Regulatory protein in the cell cycle and cyclin-
dependent kinase (cdk4/cdk6) inhibitor. The tumor 
suppressor gene p16 is commonly inactivated in many 
neoplasms. Three distinct mechanisms of p16 
inactivation have been reported in biliary neoplasms: 
deletion and point mutations of the p16 gene, and 
hypermethylation of 5’ regulatory regions of p16. It has 
been reported that 60-80% of primary biliary tract 
carcinomas had point mutations in the p16 gene. Allelic 
loss at the p16 locus on chromosome 9p21 or p16 
promoter hypermethylation occurred with sufficient 
frequency in extrahepatic bile duct carcinomas and in 
gallbladder carcinomas. Therefore, the p16 gene may







Proto-oncogene. Amplification and overexpression of 
c-erbB-2 are frequently shown in biliary tract 
carcinomas. It is suggested that c-erbB-2 expression 
may be associated with neoplastic progression in 
biliary tracts. 
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